1,050 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Congress Park Capital LLC

Key Points

• Congress Park Capital LLC has acquired 1,050 shares of Thermo Fisher Scientific Inc. for approximately $426,000, highlighting ongoing interest from institutional investors in the company.
• During the first quarter, GAMMA Investing LLC significantly increased its holdings in Thermo Fisher by 60,610.9%, now owning over 2.4 million shares valued at over $1.2 billion.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, with a yield of 0.4%, scheduled to be paid on October 15th.

Congress Park Capital LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,050 shares of the medical research company's stock, valued at approximately $426,000.

Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC raised its holdings in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG raised its position in shares of Thermo Fisher Scientific by 0.3% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after acquiring an additional 461 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $6,086,000. Finally, Voloridge Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $7,471,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Robert W. Baird raised their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Evercore ISI dropped their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, William Blair initiated coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating for the company. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $588.35.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $1.08 during mid-day trading on Friday, hitting $480.02. The stock had a trading volume of 4,241,401 shares, compared to its average volume of 1,557,193. The firm's 50 day moving average is $472.01 and its 200 day moving average is $448.95. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The stock has a market capitalization of $181.26 billion, a price-to-earnings ratio of 27.76, a PEG ratio of 2.56 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.